# Locally Advanced NSCLC Hyperfractionated RT

> **NCT03128008** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 10 (actual)

## Conditions studied

- Carcinoma, Non Small Cell Lung (NSCLC)

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Daily hyperfractionated radiation therapy

## Key facts

- **NCT ID:** NCT03128008
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2019-01-16
- **Final completion:** 2021-01-27
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03128008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03128008, "Locally Advanced NSCLC Hyperfractionated RT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03128008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*